Dohi Tomoharu, Ishihara Takayuki, Kida Hirota, Nakamura Daisuke, Kikuchi Atsushi, Kawai Tsutomu, Mori Naoki, Okamoto Naotaka, Ueda Yasunori, Shutta Ryu, Ichikawa Minoru, Mano Toshiaki, Watanabe Tetsuya, Higuchi Yoshiharu, Nishino Masami, Hida Eisuke, Sato Tomoharu, Hikoso Shungo, Nakatani Daisaku, Sotomi Yohei, Sakata Yasushi
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan.
Kansai Rosai Hospital Cardiovascular Center, 3-1-69 Inabasou, Amagasaki 660-8511, Japan.
Cardiovasc Revasc Med. 2025 Mar 30. doi: 10.1016/j.carrev.2025.03.024.
Although several clinical trials have suggested the usefulness of drug-coated balloons (DCB) for side-branch lesions, their efficacy and safety have not yet been established.
The Osaka Cardiovascular Conference (OCVC) will conduct a multicenter, randomized, open-label, controlled trial aiming to examine whether additional DCB treatment for the side branch after main vessel stenting followed by kissing balloon inflation (KBI) is superior to only KBI by conventional balloons in PCI patients with coronary bifurcation lesions. The primary endpoint is restenosis of side branches documented by scheduled or symptom-driven coronary angiography during 9-month follow-up period after the index PCI. The key secondary endpoints include major adverse cardiac event which consists of cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis, and optical coherence tomography findings. A total of 300 patients will be enrolled and followed up to 1 year.
The OCVC-BIF trial is a randomized controlled trial designed to assess whether additional DCB treatment for side branch is superior to only KBI by conventional balloons in patients with coronary bifurcation lesions undergoing PCI with main vessel stenting.
尽管多项临床试验表明药物涂层球囊(DCB)对分支病变有用,但其疗效和安全性尚未确立。
大阪心血管会议(OCVC)将开展一项多中心、随机、开放标签、对照试验,旨在研究在接受冠状动脉分叉病变经皮冠状动脉介入治疗(PCI)的患者中,主血管支架置入后对分支进行额外的DCB治疗并随后行球囊对吻扩张(KBI)是否优于仅使用传统球囊进行KBI。主要终点是在首次PCI后9个月随访期内通过预定或症状驱动的冠状动脉造影记录的分支再狭窄。关键次要终点包括主要不良心脏事件(由心源性死亡、心肌梗死、靶病变血运重建和支架血栓形成组成)以及光学相干断层扫描结果。总共将纳入300例患者并随访1年。
OCVC-BIF试验是一项随机对照试验,旨在评估在接受主血管支架置入的冠状动脉分叉病变PCI患者中,对分支进行额外的DCB治疗是否优于仅使用传统球囊进行KBI。